AP1 and AP2 in France: What Biopharma Companies Need to Know
France’s Early Access program enables eligible patients with serious, rare or disabling diseases to receive innovative medicines before conventional reimbursement is in place. AP1, or pre-MA early access, applies when a medicinal product does not yet hold a marketing authorization (MA) in the relevant indication; AP2, or post-MA early access, applies once that marketing authorization has been granted but standard reimbursement is not yet effective. AP1 and AP2 are common shorthand terms; official French documents refer to pre-AMM and post-AMM Early Access authorizations (AAP).
For US biopharma companies preparing to enter the French market, the AP1 and AP2 early access pathways can accelerate patient access while providing a strategic bridge between late-stage clinical development, EU marketing authorization, French health technology assessment, pricing and reimbursement, and commercial launch.
Updated to reflect the French Early Access framework and procedural changes effective September 1, 2026.
What is AP1 in France?
AP1 is France’s pre-MA Early Access pathway. It allows an innovative medicine to be made available in a specific indication before marketing authorization has been granted for that indication, even when the product already has an authorization in a different indication, provided the applicable unmet-need and eligibility criteria are fulfilled.
AP1 is not a clinical trial and should not be viewed simply as the French equivalent of a US expanded access program. It is an indication-based early access authorization with a defined patient population, regulatory assessment, reimbursement mechanism and mandatory data collection protocol.
The company must have submitted, or commit to submitting, a marketing authorization application for the indication concerned within a deadline set by the Haute Autorité de Santé (HAS), the French National Authority for Health. This deadline cannot exceed two years from the grant of pre-MA Early Access.
For AP1, the French National Agency for the Safety of Medicines and Health Products (ANSM) normally issues a binding opinion on the strong presumption of efficacy and safety.
Under the rules applicable to Early Access applications submitted on or after September 1, 2026, a favorable opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) on the marketing authorization in the indication concerned removes the requirement for this ANSM binding opinion.
The HAS remains responsible for granting Early Access authorization, based on its assessment of the remaining four statutory eligibility criteria.
The 5 key AP1 eligibility criteria
For a pre-MA Early Access (AP1), the following elements must effectively come together:
The disease is serious, rare or disabling
The relevant indication must concern a serious, rare or disabling disease with a significant impact on patients.
There is no appropriate therapeutic alternative available
Existing treatments must be assessed in the context of the specific indication and patient population. A treatment cannot simply be considered inappropriate because the new drug appears more convenient.
Treatment cannot be deferred
There must be urgency from the patient’s perspective: waiting for the conventional marketing authorization and reimbursement approval process would not constitute appropriate treatment.
The medicinal product is presumed innovative
HAS considers the product’s presumed innovation, including its potential value relative to a clinically relevant comparator and the available therapeutic alternatives.
Efficacy and safety are strongly presumed
For pre-MA Early Access, the available results from therapeutic clinical trials must support a strong presumption of efficacy and safety. This analysis considers the total clinical data package—not simply whether a primary endpoint has technically been met.
A typical AP1 candidate might therefore be an innovative therapy in oncology or rare diseases with advanced clinical data, a clearly defined population with high unmet medical need, limited or no appropriate treatment options, and a marketing authorization submission plan already underway.
AP1 is different from compassionate access
France operates two systems for exceptional access to medicines: Early Access and Compassionate Access. The distinction is important.
Early Access—including AP1 and AP2—is designed primarily for innovative medicines being developed toward marketing authorization and commercial availability.
By contrast, a Compassionate Access Authorization (AAC) is generally granted by ANSM at a prescriber’s request for a named patient and usually concerns medicines not being commercially developed in that indication, subject to defined exceptions. ANSM also establishes Compassionate Prescription Frameworks (CPCs) for certain off-label uses. These routes follow different authorization and monitoring rules from AP1.
The July 2021 reform replaced much of the former French temporary authorization (ATU) framework with these Early Access and Compassionate Access pathways.
What Is AP2 in France?
AP2 is the post-MA Early Access pathway. Unlike AP1, the medicine already has a valid marketing authorization in the relevant indication, but conventional reimbursement is not yet in place. For this indication, the company must have filed or commit to filing within one month of obtaining marketing authorization, an application for listing under the applicable French reimbursement scheme.
This creates a bridge between obtaining marketing authorization and completing the French market access process.
A company can apply for AP2 after an AP1, but AP1 is not a prerequisite. A pharmaceutical company may seek post-MA early access directly where its medicine meets the eligibility criteria.
The HAS decides whether the product satisfies the Early Access criteria, following assessment by its Commission de la Transparence. The subsequent evaluation for conventional reimbursement and price negotiation is a distinct process.
What AP2 means for pricing and reimbursement
Medicines authorized under the French Early Access system benefit from immediate coverage by the French health insurance system under the applicable conditions.
Where the product is not already subject to an applicable regulated hospital price or reimbursement regime, the pharmaceutical company may supply it free of charge or charge hospitals an indemnity whose amount it sets, subject to the applicable declaration and financial rules. The maximum indemnity must be declared to the CEPS within one month of the grant of the Early Access authorization.
This mechanism is sometimes described as a “free price”, but that description can be misleading. Early Access revenue is subject to statutory rebates, potential additional rebates and, ultimately, reconciliation based on the price negotiated with the CEPS or the applicable reference price. Early revenue therefore should not be treated as equivalent to the final net commercial price.
AP1 vs AP2: Key Differences at a Glance
| AP1 – Pre-MA Early Access | AP2 – Post-MA Early Access | |
|---|---|---|
| Marketing authorization status | No marketing authorization yet in the relevant indication | Marketing authorization granted in the relevant indication |
| Primary purpose | Accelerate patient access before marketing authorization | Bridge the period between marketing authorization and conventional reimbursement |
| Main decision-making authority | HAS; ANSM binding efficacy/safety opinion unless there is a favorable CHMP opinion in the relevant indication | HAS, following assessment by the Commission de la Transparence |
| Efficacy/safety requirement | Efficacy and safety must be strongly presumed from available clinical data | Benefit-risk already assessed through the marketing authorization process |
| Innovation requirement | Presumed innovation required | Presumed innovation requirement remains relevant |
| Appropriate therapeutic alternative | No appropriate therapeutic alternative available | No appropriate therapeutic alternative available |
| Urgency | Treatment cannot be deferred | Treatment cannot be deferred |
| Data collection | PUT-RD with real-world data collection and ongoing safety monitoring | PUT-RD and ongoing real-world data collection appropriate to the post-MA context |
| Maximum authorization duration | Up to 12 months, renewable | Up to 12 months, renewable |
| Pricing / reimbursement | Early Access coverage; indemnity may be charged where no administered price exists, subject to rebates and reconciliation | Same Early Access financing framework until conventional reimbursement takes over |
| Typical population | Defined pre-MA patient population with major unmet medical need | Patients within a specific authorized indication pending standard reimbursement |
| Next regulatory step | Marketing authorization filing, then post-MA continuity and reimbursement transition | Reimbursement listing request within one month of MA; standard reimbursement and CEPS price negotiation |
Early access authorizations are granted for a maximum of 12 months and may be renewed. Renewal applications must generally be submitted at least three months before the current authorization expires.
Why Early Access Matters for US Biopharma Entering France
For a US biopharma company approaching Europe for the first time, France’s Early Access programs can do more than accelerate patient access.
Reach eligible patients earlier
AP1 can make an innovative medicine available before full marketing authorization in the relevant indication, while AP2 can help bridge the interval between marketing authorization and a French conventional reimbursement decision.
For patients with a serious, rare or disabling disease and no appropriate therapeutic alternative, this can materially shorten the period before treatment becomes available.
Build the French launch pathway before conventional reimbursement
An Early Access program creates an operational bridge into French clinical practice. Healthcare professionals begin working within a defined treatment pathway, patient eligibility processes are established, pharmacovigilance becomes operational and the supply chain is tested before the full commercial launch.
This should not be confused with promotional activity. For pre-MA Early Access, measures intended to inform relevant healthcare professionals about the authorization must not constitute advertising. Such measures are subject to prior opinion by HAS and also by ANSM where it provided the binding opinion on the AP1 application; the applicable 30-day no-response rule must be observed.
The value is therefore not simply “visibility with prescribers.” It is the opportunity to establish the medical, regulatory, quality and operational infrastructure required to support prescribers and eligible patients compliantly.
Generate real-world evidence
Each Early Access Authorization operates alongside a Protocole d’Utilisation Thérapeutique et de Recueil de Données (PUT-RD)—a therapeutic use and data collection protocol.
Depending on the program, the data collected can include:
• patient characteristics;
• actual product utilization;
• effectiveness in clinical practice;
• quality-of-life information and patient reported outcomes;
• adverse events and other safety information; and
• reasons for initiation or discontinuation.
This allows companies to collect real world data before or around commercial launch and develop real world evidence that can complement the clinical trial package.
Early Access should not, however, be treated as a substitute for robust clinical trials. The strength of the clinical development plan, comparator strategy and important data generated before submission remain central to the HAS decision-making process.
Generate revenue before conventional launch
Where an indemnity is charged, Early Access can generate revenue ahead of the conventional reimbursement phase.
For pharmaceutical companies, this can partly offset the investment required to establish the French organization and accelerate access. However, the statutory rebate and final reconciliation mechanisms mean that gross Early Access revenue should not be equated with permanent net revenue.
Eligibility Criteria and Application Process
A successful AP1 France or AP2 strategy needs to be prepared well before the filing itself.
1. Assess Early Access eligibility
The first step is to confirm that the relevant indication meets the French eligibility criteria:
- serious, rare or disabling disease;
- no appropriate therapeutic alternative;
- treatment cannot be delayed; and
- presumed innovation.
For AP1, the available clinical data must additionally support the strong presumption of efficacy and safety required for pre-MA early access.
The analysis should consider existing treatments, any clinically relevant comparator, expected patient characteristics, the maturity of the development plan, safety information and the planned path toward marketing authorization.
2. Prepare the Early Access dossier
The application is submitted electronically through the HAS SÉSAME platform.
The package is broader than a simple regulatory form. Depending on the situation, it includes information relating to the medicinal product, relevant indication, clinical development, regulatory strategy, available efficacy and safety evidence, proposed product information, treatment alternatives, population, economic elements and the proposed PUT-RD.
For initial AP1 applications, HAS and ANSM may offer an optional, confidential joint pre-submission meeting, normally held two to three months before the intended filing date. This meeting is not available when a favorable CHMP opinion has been issued or one is expected during the AP1 application review, and the agencies may decline a meeting request.
Patient associations may contribute to the assessment process, while the broader French ecosystem of healthcare professionals, clinical experts and scientific societies can also be important when preparing the evidence and implementation environment.
3. Administrative validation and review
HAS currently indicates:
- approximately 10 working days for administrative admissibility; and
- a 90-day review period starting from acknowledgement of a complete application.
The clock may be suspended where additional information is requested, and an extension of up to 30 days is possible when the number of applications is exceptionally high. Other specific extensions may apply in connection with the ANSM or CHMP opinion.
HAS reported a median evaluation time of approximately 80 days for initial Early Access requests during the first four years of the system, compared with the 90-day regulatory review period.
4. Implement the PUT-RD and operational framework
Once Early Access is granted, the rights holder must make the medicine available within two months and ensure appropriate ongoing supply, data collection, pharmacovigilance and reporting systems. The medicine is generally dispensed via a hospital pharmacy (pharmacie à usage intérieur, PUI), or through the legally permitted alternative where the hospital has no PUI.
The PUT-RD can be used to support prescribers by defining patient eligibility, prescribing and dispensing conditions, follow-up requirements and real-world data collection.
Periodic synthesis reports must be supplied under the PUT-RD timetable to HAS and the competent ministries, and to ANSM where required under the applicable pre-MA procedure. They provide updated information on utilization, effectiveness, safety and the completeness of the collected data.
5. Manage the transition from AP1 to the post-MA phase
When a product benefiting from AP1 obtains its marketing authorization, the company must inform HAS without delay and manage the move to the post-MA phase; the pre-MA authorization does not simply convert into a new full AP2 application.
Under the procedure effective in September 2026, a dedicated continuity request can be filed through SÉSAME for the part of the pre-MA Early Access indication covered by the new marketing authorization. Where the scope is unchanged and the authorization does not affect the original conditions for Early Access, a fresh Commission de la Transparence opinion and a new HAS Board decision are not required. If the marketing authorization is broader or narrower than the original AP1 scope, separate post-MA or pre-MA applications may be appropriate for the unmatched population.
The company must also submit the applicable French reimbursement listing request within one month of obtaining marketing authorization in the indication concerned, while health technology assessment, pricing and reimbursement activities continue toward the conventional system.
6. Prepare the French Exploitant model
This is one of the most important France-specific issues for US biopharma companies.
French law separates holding the rights to a medicine from the regulated pharmaceutical activities involved in its exploitation.
The Early Access application itself is filed by the holder of the exploitation rights or its representative. However, exploitation of the medicine in France—including wholesale supply or free provision, medical information, pharmacovigilance, batch tracking and recalls—must take place through the appropriately authorized French pharmaceutical establishment framework.
The authorized Exploitant may be the marketing or Early Access authorization holder itself, a different authorized company acting on its behalf, or both, with a clear allocation of their respective exploitation activities and responsibilities (learn more on French Exploitant Status here).
For a US company without a French affiliate, this creates an operational decision very early in the market access timeline: outsource the Exploitant role, acquire an existing structure, or build one internally.
Common Challenges for US Biopharma Companies
Choosing the Right French Exploitant Model
Many US biotech companies approach the European market with an EU regulatory strategy but no pharmaceutical infrastructure in France.
France requires specific pharmaceutical activities to be carried out through an authorized Exploitant. This involves dedicated pharmaceutical governance, a quality management system, appropriate procedures and a Pharmacien Responsable (Responsible Pharmacist).
However, establishing a French pharmaceutical entity is not the only option. Companies can work with an existing authorized Exploitant, acquire an authorized structure or establish their own.
Choosing the right model early is essential to align regulatory requirements, operational readiness, timelines and long-term commercialization plans.
Navigating French Regulatory and Market Access Requirements
The French Early Access framework combines regulatory assessment, health technology assessment, reimbursement and operational requirements.
For US companies familiar with FDA pathways, understanding the respective roles of the HAS, ANSM, Commission de la Transparence and CEPS is essential.
Beyond the regulatory submission, the maturity of clinical evidence, the availability of appropriate therapeutic alternatives, French clinical practice and the positioning of the product within the treatment pathway can significantly influence eligibility and timing.
An effective Early Access strategy must therefore anticipate the transition from AP1 or AP2 to conventional reimbursement and commercial launch.
Ensuring Operational Readiness and Compliance
Obtaining Early Access authorization is only one step. Successful implementation requires coordinated management of multiple activities, including patient access, hospital arrangements, product supply, pharmacovigilance and data collection under the PUT-RD.
These activities involve ongoing regulatory obligations, including patient follow-up, safety monitoring and periodic data reporting.
For US biopharma companies without an established French organization, coordinating these responsibilities across local providers and internal teams can be particularly challenging.
Early Access therefore needs to be managed as an integrated regulatory and operational program, rather than an isolated market access submission.
How Can AzurBio Help?
AzurBio supports US and international biopharma companies in designing and implementing their French Early Access strategy, from initial eligibility assessment through operational implementation and preparation for commercial launch.
Combining strategic regulatory expertise with practical pharmaceutical operations, AzurBio offers integrated support across:
Early Access strategy
AP1/AP2 eligibility assessment, regulatory planning and alignment with the broader European development and launch strategy.
Regulatory submissions
HAS and ANSM interactions, dossier preparation and support throughout the assessment process.
Early Access implementation
PUT-RD implementation, patient data collection, hospital arrangements and operational coordination.
Pharmaceutical compliance
Pharmacovigilance, quality oversight, medical information and coordination of supply and distribution activities.
Market access transition
Preparation for reimbursement and management of the transition from Early Access to commercial availability.
French operating model
Selection and implementation of the appropriate Exploitant structure, aligned with the company’s objectives and timeline.
This integrated approach enables companies to address regulatory, operational and market access requirements within a coordinated French entry strategy.
Unlock France: Borrow, Buy or Build
Through Unlock France, AzurBio offers three flexible models to meet France’s Exploitant requirements, depending on each company’s timeline, resources and long-term objectives.
Borrow — Partner with AzurBio Pharma France as Your Exploitant
For companies seeking to enter France without establishing their own pharmaceutical infrastructure, AzurBio Pharma France can act as their authorized French Exploitant.
This model provides access to an existing ANSM-authorized structure, pharmaceutical governance and quality infrastructure, subject to the agreed scope of activities and product-specific operational requirements.
It can support Early Access and subsequent commercialization while allowing companies to defer or avoid the investment required to establish their own Exploitant.
Buy — Acquire an Existing Exploitant structure
For companies seeking a permanent French presence without building an organization entirely from scratch, AzurBio offers the opportunity to acquire an existing French legal entity holding an ANSM Exploitant authorization.
The structure includes an established regulatory and quality framework, with AzurBio supporting the acquisition, regulatory due diligence and operational transition.
Any necessary regulatory changes, pharmaceutical appointments and product-specific readiness activities are addressed as part of the implementation plan.
Build — Establish your own Exploitant
For companies committed to developing an in-house French pharmaceutical organization, AzurBio provides end-to-end support for establishing an Exploitant.
Services include regulatory planning, preparation and submission of the ANSM authorization dossier, QMS and SOP development, Pharmacien Responsable arrangements and preparation for operational readiness and regulatory inspections.
A Flexible Path from Early Access to Commercial Launch
Early Access is often the first step in a broader French market-entry strategy. The appropriate Exploitant model may evolve as products progress toward commercial launch.
Through Unlock France, AzurBio combines flexible Borrow, Buy and Build solutions with regulatory, market access and pharmaceutical expertise, helping companies implement an operating model aligned with their immediate patient access needs and longer-term commercial objectives.
Experience across the European launch pathway
Established with the guidance of a Strategic Committee bringing senior leadership experience from international biopharma companies, AzurBio today combines strategic insight with hands-on regulatory, market access and pharmaceutical expertise to support international biopharma companies entering the French market.
Frequently Asked Questions
Can a company apply for AP2 without going through AP1?
Yes. AP2 can be requested directly for a medicinal product that already has marketing authorization in the relevant indication but is not yet covered by conventional reimbursement. AP1 is therefore not a prerequisite.
How long does the AP1 or AP2 process take?
The HAS assesses administrative admissibility within 10 working days, followed by a 90-day regulatory review period starting from acknowledgement of a complete application. The review period may be suspended if additional information is required or extended in exceptional circumstances.
For eligible pre-MA Early Access applications, optional HAS/ANSM pre-submission meetings should be scheduled approximately two to three months before the intended filing date.
What happens when Early Access ends?
When a medicine becomes eligible for conventional reimbursement, patient access transitions to the standard reimbursement framework.
For patients whose treatment was initiated during Early Access, French regulations require continuity of treatment for at least one year after Early Access coverage ends, subject to specific exceptions, including serious safety concerns.
If conventional reimbursement is not yet available, the previous Early Access reimbursement conditions remain applicable for the first three months of this continuity period.
New patients can generally no longer initiate treatment under the expired Early Access authorization. The company must also fulfil its remaining pharmacovigilance, data reporting and financial obligations.
Planning an AP1 or AP2 Program in France?
Whether you are preparing an Early Access application or defining your French Exploitant model, explore Unlock France or contact AzurBio to discuss your regulatory and operational strategy.